No Data
No Data
Vanda Pharmaceuticals to Commercialize Treatment of Multiple Sclerosis in the US
Vanda Pharmaceuticals (VNDA) said late Thursday it is now allowed to commercialize Ponvory, or ponesimod, in the US. The company said the move follows the transfer of ownership of the US new drug appl
Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference
WASHINGTON, May 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2024 Global Healthcare Conference in New
Express News | Vanda Pharmaceuticals Gains Ownership Of The U.S. NDA And IND Applications For PONVORY From A Johnson & Johnson Company, Which Now Fully Allows Vanda To Commercialize PONVORY In The U.S
Express News | Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for Ponvory®
Vanda Pharmaceuticals Announces Presentations at SLEEP 2024
WASHINGTON, May 29, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2024, to be held in Houston, TX from June 1 through June 5, 2024. The
Express News | Vanda Pharmaceuticals Rejects Revised Unsolicited Acquisition Proposal From Future Pak, Concluding It Undervalues The Company; Board Unanimously Decides Proposal Is Not In The Best Interests Of Shareholders